MedTrace Logo

A Study of Avutometinib for People With Solid Tumor Cancers

NCT06104488 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2026-02-25

No results posted yet for this study

Summary

The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults. Researchers will look for the highest dose of avutometinib that is safe and cause few or mild side effects.

Conditions

  • Refractory Cancer
  • CNS Tumors
  • CNS Tumor, Adult
  • CNS Tumor, Childhood
  • MAP Kinase Family Gene Mutation
  • NF1
  • Plexiform Neurofibroma
  • Low-grade Glioma
  • Optic Pathway Gliomas
  • Neuroblastoma
  • Primary Brain Tumor
  • Solid Tumor
  • Solid Tumor, Adult
  • Solid Carcinoma
  • Central Nervous System Tumor

Interventions

DRUG

Avutometinib

Participants will receive oral avutometinib once daily twice a week, three weeks on/ 1week off, for a period of 28 days per cycle

Sponsors & Collaborators

Principal Investigators

  • Sameer Farouk Sait, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
3 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-20
Primary Completion
2029-10-20
Completion
2029-10-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06104488 on ClinicalTrials.gov